Clinical Trial Failure Risk: Their lead drug candidate, Ibezapolstat, may not successfully complete clinical trials or demonstrate sufficient safety and efficacy for regulatory approval.

Regulatory Approval Risk: Even with positive clinical trial results, Acurx may not receive necessary regulatory approvals from agencies like the FDA, delaying or preventing market entry.

Funding and Liquidity Risk: As a development-stage company, Acurx will require significant additional capital to fund ongoing clinical trials and operations, which may not be available on favorable terms or at all.